China’s top drug regulator has launched a one-year pilot program that will halve the current standard review time for investigational new drug (IND) applications for innovative drugs to 30 working days from the date the application is accepted.
China Pilots Scheme To Halve IND Review Time For Innovative Drugs
China’s top drug regulator is implementing a pilot program offering shorter review times for IND applications to improve the quality and efficiency of clinical studies and stimulate the country’s innovative drug sector.
